Home/Filings/4/0001209191-23-033401
4//SEC Filing

Sandborn William J. 4

Accession 0001209191-23-033401

CIK 0001851194other

Filed

May 31, 8:00 PM ET

Accepted

Jun 1, 5:53 PM ET

Size

10.2 KB

Accession

0001209191-23-033401

Insider Transaction Report

Form 4
Period: 2023-05-31
Transactions
  • Sale

    Common Stock

    2023-05-31$34.26/sh10,629$364,15548,389 total
  • Exercise/Conversion

    Common Stock

    2023-05-31$0.20/sh+10,629$2,12659,018 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2023-05-3110,62910,790 total
    Exercise: $0.20Exp: 2029-03-27Common Stock (10,629 underlying)
Holdings
  • Common Stock

    (indirect: By Spouse)
    34,662
Footnotes (3)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2022.
  • [F2]Represents the weighted average share price of an aggregate total of 10,629 shares sold in the price range of $33.645 to $34.565. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F3]Subject to the Reporting Person's spouse continuing to be a Service Provider (as defined in the Issuer's 2019 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the total shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 6, 2019.

Issuer

Ventyx Biosciences, Inc.

CIK 0001851194

Entity typeother

Related Parties

1
  • filerCIK 0001923805

Filing Metadata

Form type
4
Filed
May 31, 8:00 PM ET
Accepted
Jun 1, 5:53 PM ET
Size
10.2 KB